TAFINLAR (dabrafenib)
TherapyNovartis
TAFINLAR (dabrafenib) from Novartis is a BRAF inhibitor used in BRAF V600-mutant cancers.
Approvals
3
Indications
1
Biomarkers
1
Mapped tests
3
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and TAFINLAR. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where TAFINLAR is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Melanoma Solid Tumor · Melanoma | BRAF
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for TAFINLAR.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering TAFINLAR for eligible patients.
Test
FoundationOne CDx
Foundation Medicine, Inc.
Method
NGS
Specimen
Tissue (FFPE)
1 approvalView test profile →
Test
MI Cancer Seek (MCS)
Caris Life Sciences
Method
NGS
Specimen
Tissue (FFPE)
1 approvalView test profile →
Test
THXID BRAF Kit
bioMérieux Inc.
1 approvalView test profile →